MIRA Pharmaceuticals (NASDAQ:MIRA)

BRIEF

published on 11/20/2024 at 13:49, 1 day 3 hours ago

MIRA Pharmaceuticals lance des essais cliniques sur le kétamir-2

Essai Clinique Ketamir-2 MIRA Pharmaceutique Technologie PainCart Traitement Non Addictif
BRIEF

published on 11/20/2024 at 13:49, 1 day 3 hours ago

MIRA Pharmaceuticals Initiates Ketamir-2 Clinical Trials

Clinical Trial MIRA Pharmaceuticals Ketamir-2 PainCart Technology Non-addictive Treatment
PRESS RELEASE

published on 11/20/2024 at 13:44, 1 day 3 hours ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Pharmaceuticals progresses towards clinical-stage status with Phase I/IIa trial announcement on Ketamir-2, a novel oral ketamine analog, for pain management. CHDR's PainCart technology leveraged

Pain Management MIRA Pharmaceuticals Ketamir-2 Clinical-stage Company Phase I/IIa Trial
BRIEF

published on 10/28/2024 at 12:35, 24 days 4 hours ago

MIRA Pharmaceuticals révèle des résultats précliniques prometteurs pour le kétamir-2

Résultats Précliniques Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Désignation De La FDA
BRIEF

published on 10/28/2024 at 12:35, 24 days 4 hours ago

MIRA Pharmaceuticals Reveals Promising Preclinical Results for Ketamir-2

Preclinical Results MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain FDA Designation
PRESS RELEASE

published on 10/28/2024 at 12:30, 24 days 4 hours ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
MIRA Pharmaceuticals announces promising preclinical results for Ketamir-2, a potential breakthrough therapy surpassing current treatments. Study shows 60% greater efficacy than gabapentin in reducing chemotherapy-induced pain, to be presented at Pain Therapeutics Summit

Pain Management Preclinical Results MIRA Pharmaceuticals Ketamir-2 Breakthrough Therapy
BRIEF

published on 10/21/2024 at 13:35, 1 month ago

MIRA Pharmaceuticals présente le kétamir-2 comme une alternative prometteuse au traitement de la douleur

Étude Préclinique Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Gabapentine Et Prégabaline
BRIEF

published on 10/21/2024 at 13:35, 1 month ago

MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Pain Relief Alternative

Preclinical Study MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Gabapentin And Pregabalin
PRESS RELEASE

published on 10/21/2024 at 13:30, 1 month ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD

Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 09/27/2024 at 13:35, 1 month 24 days ago

MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pain Therapeutics Summit

1 2 ... 4

Published on 11/21/2024 at 16:30, 21 minutes ago

The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 50 minutes ago

Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 51 minutes ago

Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 51 minutes ago

Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 51 minutes ago

Isaac Ullatil Joins Wellstack Board of Directors

View all ACCESSWIRE

Published on 11/21/2024 at 16:00, 51 minutes ago

Director/PDMR Shareholding
Published on 11/21/2024 at 15:41, 1 hour 9 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 1 hour 27 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 1 hour 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 1 hour 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc

View all EQS

Published on 11/21/2024 at 06:58, 9 hours 53 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 53 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 53 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 43 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 21 hours 31 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE

News